Clinical trial / 2013
A randomized trial protocol describes testing whether oral sodium bicarbonate supplementation slows kidney function decline in chronic kidney disease.
This study protocol outlines the SoBic-study, a single-center, randomized, controlled, open-label trial in Vienna. A planned 200 patients with chronic kidney disease stages 3 or 4 and chronic metabolic acidosis (serum HCO3- <21 mmol/L) will be randomized 1:1 to either high-dose oral sodium bicarbonate (target serum HCO3- 24±1 mmol/L) or rescue therapy (target 20±1 mmol/L) for two years. The primary outcome is change in renal function assessed by eGFR after two years.
- Study type
- Randomized controlled open-label trial protocol
- Who was studied
- Planned 200 patients with chronic kidney disease stage 3 or 4 and serum HCO3- <21 mmol/L
- What was measured
- eGFR after 2 years; markers of bone metabolism, death rates, progression to renal replacement therapy, and adverse events
THE PAPER
Effect of oral sodium bicarbonate supplementation on progression of chronic kidney disease in patients with chronic metabolic acidosis: study protocol for a randomized controlled trial (SoBic-Study).
Gaggl M, Cejka D, Plischke M, Heinze G, Fraunschiel M, Schmidt A, Hörl WH, Sunder-Plassmann G. Trials, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.